vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and WARRIOR MET COAL, INC. (HCC). Click either name above to swap in a different company.
WARRIOR MET COAL, INC. is the larger business by last-quarter revenue ($458.6M vs $247.1M, roughly 1.9× ANI PHARMACEUTICALS INC). WARRIOR MET COAL, INC. runs the higher net margin — 15.8% vs 11.1%, a 4.6% gap on every dollar of revenue. On growth, WARRIOR MET COAL, INC. posted the faster year-over-year revenue change (52.1% vs 29.6%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 7.5%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Warrior Met Coal, Inc. (ticker HCC) is a U.S.-headquartered mining enterprise that produces and distributes high-grade metallurgical coal, a key raw material for steel production. It serves steel manufacturers and industrial clients across core markets including North America, Europe, and Asia.
ANIP vs HCC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $458.6M |
| Net Profit | $27.5M | $72.3M |
| Gross Margin | — | 36.7% |
| Operating Margin | 14.1% | 17.3% |
| Net Margin | 11.1% | 15.8% |
| Revenue YoY | 29.6% | 52.1% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $458.6M | ||
| Q4 25 | $247.1M | $384.0M | ||
| Q3 25 | $227.8M | $328.6M | ||
| Q2 25 | $211.4M | $297.5M | ||
| Q1 25 | $197.1M | $299.9M | ||
| Q4 24 | $190.6M | $297.5M | ||
| Q3 24 | $148.3M | $327.7M | ||
| Q2 24 | $138.0M | $396.5M |
| Q1 26 | — | $72.3M | ||
| Q4 25 | $27.5M | $23.0M | ||
| Q3 25 | $26.6M | $36.6M | ||
| Q2 25 | $8.5M | $5.6M | ||
| Q1 25 | $15.7M | $-8.2M | ||
| Q4 24 | $-10.3M | $1.1M | ||
| Q3 24 | $-24.2M | $41.8M | ||
| Q2 24 | $-2.3M | $70.7M |
| Q1 26 | — | 36.7% | ||
| Q4 25 | — | 29.5% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | 23.9% | ||
| Q1 25 | — | 18.1% | ||
| Q4 24 | — | 23.1% | ||
| Q3 24 | — | 29.3% | ||
| Q2 24 | — | 34.1% |
| Q1 26 | — | 17.3% | ||
| Q4 25 | 14.1% | 9.0% | ||
| Q3 25 | 15.9% | 6.3% | ||
| Q2 25 | 6.6% | 2.6% | ||
| Q1 25 | 13.3% | -5.8% | ||
| Q4 24 | -2.3% | -1.4% | ||
| Q3 24 | -13.8% | 11.9% | ||
| Q2 24 | 3.7% | 17.9% |
| Q1 26 | — | 15.8% | ||
| Q4 25 | 11.1% | 6.0% | ||
| Q3 25 | 11.7% | 11.1% | ||
| Q2 25 | 4.0% | 1.9% | ||
| Q1 25 | 8.0% | -2.7% | ||
| Q4 24 | -5.4% | 0.4% | ||
| Q3 24 | -16.3% | 12.7% | ||
| Q2 24 | -1.7% | 17.8% |
| Q1 26 | — | $1.37 | ||
| Q4 25 | $1.14 | $0.43 | ||
| Q3 25 | $1.13 | $0.70 | ||
| Q2 25 | $0.36 | $0.11 | ||
| Q1 25 | $0.69 | $-0.16 | ||
| Q4 24 | $-0.45 | $0.02 | ||
| Q3 24 | $-1.27 | $0.80 | ||
| Q2 24 | $-0.14 | $1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $233.2M |
| Total DebtLower is stronger | — | $154.4M |
| Stockholders' EquityBook value | $540.7M | — |
| Total Assets | $1.4B | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $233.2M | ||
| Q4 25 | $285.6M | $300.0M | ||
| Q3 25 | $262.6M | $336.3M | ||
| Q2 25 | $217.8M | $383.3M | ||
| Q1 25 | $149.8M | $454.9M | ||
| Q4 24 | $144.9M | $491.5M | ||
| Q3 24 | $145.0M | $583.2M | ||
| Q2 24 | $240.1M | $709.0M |
| Q1 26 | — | $154.4M | ||
| Q4 25 | — | $154.3M | ||
| Q3 25 | — | $154.1M | ||
| Q2 25 | — | $153.9M | ||
| Q1 25 | — | $153.8M | ||
| Q4 24 | — | $153.6M | ||
| Q3 24 | — | $153.5M | ||
| Q2 24 | — | $153.3M |
| Q1 26 | — | — | ||
| Q4 25 | $540.7M | $2.1B | ||
| Q3 25 | $505.8M | $2.1B | ||
| Q2 25 | $436.8M | $2.1B | ||
| Q1 25 | $418.6M | $2.1B | ||
| Q4 24 | $403.7M | $2.1B | ||
| Q3 24 | $405.9M | $2.1B | ||
| Q2 24 | $455.8M | $2.0B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $1.4B | $2.8B | ||
| Q3 25 | $1.4B | $2.7B | ||
| Q2 25 | $1.3B | $2.6B | ||
| Q1 25 | $1.3B | $2.6B | ||
| Q4 24 | $1.3B | $2.6B | ||
| Q3 24 | $1.3B | $2.6B | ||
| Q2 24 | $920.8M | $2.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $76.1M | ||
| Q3 25 | $44.1M | $104.7M | ||
| Q2 25 | $75.8M | $37.5M | ||
| Q1 25 | $35.0M | $10.9M | ||
| Q4 24 | $15.9M | $54.2M | ||
| Q3 24 | $12.5M | $62.2M | ||
| Q2 24 | $17.4M | $147.0M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 3.31× | ||
| Q3 25 | 1.66× | 2.86× | ||
| Q2 25 | 8.87× | 6.70× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 47.68× | ||
| Q3 24 | — | 1.49× | ||
| Q2 24 | — | 2.08× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
HCC
| Sales | $448.5M | 98% |
| Other revenues | $10.1M | 2% |
